Amylin - The Comeback Company

AMYLIN PHARMACEUTICALS: THE TREND CONTINUES UP (AMLN) Jan 27, 2011 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Amylin Pharmaceuticals (NASDAQ:AMLN) on December 13, 2010 at $13.88. In approximately 2 months, Amylin Pharmaceuticals has returned 19.6% as of today's recent price of $16.59.

 

Piper Jaffray raises Amylin Pharma to overweight, 27 Jan 2011 (Reuters)
Amylin Pharmaceuticals Inc: * Piper Jaffray raises Amylin Pharmaceuticals Inc to overweight from neutral * Piper Jaffray raises Amylin Pharmaceuticals Inc price target to $20 from $14 * Piper Jaffray upgrades Amylin following agreement with FDA for study design that reduces tqt trial risk

 

See You Tonight at “San Diego’s Fight Against Diabesity” Luke Timmerman 1/27/11
The program starts at 6 pm, and the usual networking over drinks and food (healthy stuff, I’m sure) will get going around 7:30 pm. The event will be held at Amylin Pharmaceuticals headquarters, at 9360 Towne Centre Drive in San Diego. We have an all-star lineup of speakers seeking to attack the diabetes and obesity epidemics a number of different ways. The slate includes: Dan Bradbury, CEO, Amylin Pharmaceuticals; Jack Lief, CEO, Arena Pharmaceuticals. We’re setting aside some space in the networking area for entrepreneurs from Freedom Meditech, DPS Health, and Corengi to offer “demos” of their new product strategies. Who knows, maybe one of these little companies will grow up to be the next Amylin of their own markets. See you there tonight.

 

Bydureon in Europe first half of this year. "We'll have plenty (of Bydureon). I mean, we have adequate capacity at our facility in Ohio. And I would remind you that at this time, that facility is currently producing products to be used in Europe for the European launch of BYDUREON, which we are hopeful will occur in the first half of this year."

 

Dan and his leadership team is bringing back the "American dream". AMLN has been "illuminated!"

 

This entire thread is a pile of shit.

 

Amylin Timeline Shortened. ....."Investors are a forward-looking bunch. Their optimism owes to the timeline for Bydureon, the company's once-weekly version of Byetta, designed using Alkermes's (Nasdaq: ALKS) extended-release technology. After getting the FDA to sign off on its trial design, Amylin plans to start the trial early next month, and it's now guiding for resubmitting the drug in the second half of the year. While that technically the same timeline in the worst-case scenario, at least there's a possibility of an earlier submission."

 

Bydureon in Europe first half of this year. Lilly will need to be very agressive in the launch. How the sales progress there will be a 1.5x indicator on how the sales will go in the US. This is probably the most important item for 2011. If sales take off and Lira sales drop!!!! We should be in good shape.

 

No fear. Rally slowed down by concerns in Egypt. Analysts predict move to positive territory and reach $24 in next few weeks.

 

Best PR in 2011. These big investors got our messaging..."San Diego’s Fight Against Diabesity" The Photo Gallery...http://www.xconomy.com/san-diego/2011/01/28/san-diegos-fight-against-diabesity-the-photo-gallery/

 

OREX news tomorrow will determine the fate of AMLN.

 

Shockwave hours from now.

 

Huge party at 12841 High Bluff Drive. You're all invited for drinks and dip in the ocean water before sunset.

 

Coming back from the grave.....

 

Amln is really seeing a big POP in the pps due to its almost GUARANTEED success in the anti-obesity field, as reflected in today's pps AND volume! And of course, martyha, from the IV board, who is known "far and wide" for his brilliant predictions of success w/amln's two existing drugs, and his "unbiased" and "modest" appraisals over MANY years re: bydureon's "approval", has again MODESTLY predicted amln's BRILLIANT future! One can only thank their "lucky stars" for the "GENIUS" of those individuals who have been so "responsible" for leading those of "US" less knowledgeable to the "riches" that we've "accumulated" thru their "wisdom"
CONGRATS TO ALL AMLN LONGS-THE "FUTURE" IS "OURS" (as it has been for the pasts DECADE AND A HALF)!!!!

 

Amylin has the best management team with experienced leaderships. We have over 80% of employees engaged. While other obesity programs (Orexigen, Arena, Vivus) are on respirators, our obesity program is moving forward steadily. Our INTO program could capture 90% of the obesity market. Leptin in a capsule could be comparable to the iPhone 5.

 

Like Coke, Amylin is the "real deal". Institution investors are bullish about Amylin's future.
Institutions strongly buy AMLN 15-Feb-11 09:16 am
FMR LLC 21,584,936 48,257 $335,214
ICAHN CAPITAL LP 14,381,925 1,410,597 $223,351
BANK OF NEW YORK MEL... 8,082,212 1,183,511 $125,517
OPPENHEIMER FUNDS IN... 6,704,250 1,613,500 $104,117

 

Be optimistic. Daily news is just a snapshot in time. We've encountered another bump on the road and will recover strongly as we did many times before. It's the nature of our business. Look at the economy over the past few year. Look at what's happening all over the world. There are worst things happening globally. We are all here to "challenging science and changing lives". Stick together and support Dan and his management team. They should be credited for supporting all of you and diverting layoffs. Reach out, gain alignment, embrace and value their leadership.

 

Listen to the experts. Downgraded to $9 4-Mar-11 10:12 am
NEW YORK (TheStreet) -- STOCK COMMENTS / EPS CHANGES Amylin Pharmaceuticals (AMLN_) numbers lowered at Goldman. Shares of AMLN now seen reaching $9, according to Goldman Sachs. Estimates also cut, following negative Bydureon data. Sell rating.

 

The rosie comments are coming from HR, senior mgnt or Bradbury's bitch. No one else in their right mind would suggest this is "only a bump in the road".